Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q4 FY26 results · Jan–Mar 2026
Bliss GVS Pharma reported revenue from operations of ₹256.99 crore (up 29.8% from Q4 FY25) and net profit of ₹37.00 crore (up 122.2% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 256.99 | 197.99 | +29.8% | 218.25 | +17.8% |
| Other income | 11.16 | 12.07 | −7.5% | 18.46 | −39.5% |
| Total income | 268.15 | 210.05 | +27.7% | 236.71 | +13.3% |
| Profit before tax | 44.95 | 23.44 | +91.8% | 40.90 | +9.9% |
| Net profit for the period | 37.00 | 16.65 | +122.2% | 24.78 | +49.3% |
| Attributable to shareholders of the company | 35.58 | 15.54 | +128.9% | 23.27 | +52.9% |
| EPS, basic (₹) | 3.37 | 1.47 | +129.3% | 2.20 | +53.2% |
| Net margin (%) | 14.4 | 8.4 | 11.4 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 211.54 | 156.00 | +35.6% | 164.68 | +28.5% |
| Other income | 9.30 | 9.36 | −0.6% | 10.23 | −9.1% |
| Total income | 220.84 | 165.36 | +33.5% | 174.91 | +26.3% |
| Profit before tax | 44.15 | 14.36 | +207.6% | 25.29 | +74.6% |
| Net profit for the period | 32.42 | 11.45 | +183.1% | 18.61 | +74.2% |
| EPS, basic (₹) | 3.06 | 1.08 | +183.3% | 1.76 | +73.9% |
| Net margin (%) | 15.3 | 7.3 | 11.3 |
Consolidated
- Filed with BSE
- 12 May 2026, 22:54 IST
- Board meeting
- 12 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 May 2026, 22:54 IST
- Board meeting
- 12 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE